[go: up one dir, main page]

WO2021202669A3 - Nucleoside and nucleotide conjugate compounds and uses thereof - Google Patents

Nucleoside and nucleotide conjugate compounds and uses thereof Download PDF

Info

Publication number
WO2021202669A3
WO2021202669A3 PCT/US2021/025095 US2021025095W WO2021202669A3 WO 2021202669 A3 WO2021202669 A3 WO 2021202669A3 US 2021025095 W US2021025095 W US 2021025095W WO 2021202669 A3 WO2021202669 A3 WO 2021202669A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
nucleoside
nucleotide conjugate
conjugate compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/025095
Other languages
French (fr)
Other versions
WO2021202669A2 (en
Inventor
Frank Shujie HOU
Jian XUE
Yushan ZHAO
Dezu MIAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reyoung Drug Discovery Co Ltd
Reyoung Corp
Original Assignee
Reyoung Drug Discovery Co Ltd
Reyoung Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reyoung Drug Discovery Co Ltd, Reyoung Corp filed Critical Reyoung Drug Discovery Co Ltd
Publication of WO2021202669A2 publication Critical patent/WO2021202669A2/en
Publication of WO2021202669A3 publication Critical patent/WO2021202669A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

This disclosure provides nucleoside and nucleotide conjugate compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders, such as viral infections and cancers.
PCT/US2021/025095 2020-04-01 2021-03-31 Nucleoside and nucleotide conjugate compounds and uses thereof Ceased WO2021202669A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003645P 2020-04-01 2020-04-01
US63/003,645 2020-04-01

Publications (2)

Publication Number Publication Date
WO2021202669A2 WO2021202669A2 (en) 2021-10-07
WO2021202669A3 true WO2021202669A3 (en) 2021-12-02

Family

ID=75625662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025095 Ceased WO2021202669A2 (en) 2020-04-01 2021-03-31 Nucleoside and nucleotide conjugate compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2021202669A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024069235A2 (en) 2022-09-30 2024-04-04 Sixfold Bioscience Ltd. Compositions containing oligonucleotides with theranostic applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066189A1 (en) * 2003-12-30 2005-07-21 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
EP2860185A1 (en) * 2013-10-09 2015-04-15 Zentiva, k.s. An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof
CN102850402B (en) * 2011-06-28 2016-08-03 李勤耕 Acyclonucleosides cyclic phosphate esters derivative, its preparation method and medical usage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2682397B1 (en) 2000-07-21 2017-04-19 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
CN102199181B (en) 2004-07-21 2014-09-17 吉利德制药有限责任公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AR071395A1 (en) 2008-04-23 2010-06-16 Gilead Sciences Inc 1'-SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066189A1 (en) * 2003-12-30 2005-07-21 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
CN102850402B (en) * 2011-06-28 2016-08-03 李勤耕 Acyclonucleosides cyclic phosphate esters derivative, its preparation method and medical usage
EP2860185A1 (en) * 2013-10-09 2015-04-15 Zentiva, k.s. An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AUBER Y: "Synthesis and anti-HIV-1 integrase activity of modified dinucleotides", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 1 January 2009 (2009-01-01), pages 5029 - 5044, XP055826603 *
AUBERT Y ET AL: "Synthesis and anti-HIV-1 integrase activity of modified dinucleotides", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 44, no. 12, 1 December 2009 (2009-12-01), pages 5029 - 5044, XP026776617, ISSN: 0223-5234, [retrieved on 20090909], DOI: 10.1016/J.EJMECH.2009.09.007 *

Also Published As

Publication number Publication date
WO2021202669A2 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
EP4566675A3 (en) Heterocyclic compounds as immunomodulators
WO2020160193A3 (en) Compounds and uses thereof
JO2755B1 (en) Use of 2-6 (3- amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrilfor treating diabetes,cancer , autoimmune disorders and hiv infection
MX2023012981A (en) Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use.
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
SA523440384B1 (en) Phospholipid compounds and uses thereof
EP4596543A3 (en) Farnesoid x receptor agonists and uses thereof
MY144616A (en) Substituted dihydroquinazolines
EP4537828A3 (en) Phospholipid compounds and uses thereof
MX2023009685A (en) Tyk2 inhibitors and uses thereof.
EP4252755A3 (en) Therapeutic compounds
MX2023010711A (en) Phenalkylamines and methods of making and using the same.
WO2021262910A3 (en) Tubulysins and protein-tubulysin conjugates
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2022001261A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.
MX2021013602A (en) JAK INHIBITORS.
MX2023003675A (en) Hsd17b13 inhibitors and uses thereof.
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MX2022011576A (en) Nlrp3 modulators.
MX2024006064A (en) Crystalline composition of tildacerfont and methods of use and preparation thereof.
MX2023001445A (en) 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders.
WO2022106902A3 (en) Benzenesulfonamide derivatives and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21720632

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21720632

Country of ref document: EP

Kind code of ref document: A2